3 Reasons Why Investors Should Love Regeneron's Q3 Update
Regeneron Pharmaceuticals (NASDAQ: REGN) announced its third-quarter earnings before the market opened on Thursday. Based on the stock's move, you might think that those results weren't very good. Regeneron's share price slipped more than 3% at one point in intraday trading.
The reality, though, is that Regeneron actually delivered a strong performance in the third quarter. Pharmaceutical stocks are under pressure this week because Democrats reached a deal on drug pricing reform. But don't let that overshadow Regeneron's good news. Here are three reasons why investors should love the company's Q3 update.
Image source: Getty Images.
Source Fool.com
